You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Claims for Patent: 8,263,120

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,263,120

Title:	Oral antimicrobial pharmaceutical compositions
Abstract:	The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon.
Inventor(s):	Ajani; Mauro (Milan, IT), Bozzella; Roberta (Milan, IT), Celasco; Giuseppe (Genoa, IT), Villa; Roberto (Lecco, IT)
Assignee:	Cosmo Technologies Ltd. (Dublin, IE)
Application Number:	13/451,111
Patent Claims:	1. A controlled release oral pharmaceutical composition comprising: (1) a tablet core comprising: a) rifamycin SV in an amount effective for the treatment of an infection of the colon; b) a lipophilic substance having a melting point less than about 90.degree. C.; c) lecithin; and d) a hydrophilic substance comprising a carboxyvinyl polymer or carboxyvinyl copolymer; and (2) a coating on said tablet core, said coating comprising a gastro-resistant substance. 2. The composition of claim 1, wherein said rifamycin SV comprises from about 20% to about 60% by weight of the total weight of said composition. 3. The composition of claim 1, wherein said lipophilic substance comprises from about 1% to about 3.4% by weight of the total weight of the composition. 4. The composition of claim 1, wherein said hydrophilic substance comprises from about 8.4% to about 23% by weight of the total weight of the composition. 5. The composition of claim 1, wherein said gastro-resistant substance comprises at least one methacrylic acid polymer. 6. The composition of claim 1, wherein a) said rifamycin SV comprises from about 20% to about 60% by weight of the total weight of said composition; b) said lipophilic substance comprises from about 1% to about 3.4% by weight of the total weight of the composition; c) said hydrophilic substance comprises from about 8.4% to about 23% by weight of the total weight of the composition; and d) said gastro-resistant substance comprises at least one methacrylic acid polymer. 7. The composition of claim 1, wherein said composition is resistant to dissolution for 2 hours in an environment at pH 1. 8. The composition of claim 1, wherein said composition is resistant to dissolution for 1 hour in an environment at pH 6.4. 9. The composition of claim 1, wherein said composition is resistant to dissolution for 2 hours in an environment at pH1 and is resistant to dissolution for 1 hour in an environment at pH 6.4. 10. The composition of claim 1, further comprising mannitol, magnesium stearate, titanium dioxide, talc, and triethylcitrate. 11. The composition of claim 1, wherein said infection of the colon is travellers' diarrhea.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.